Cover Image
市場調查報告書

全球癌症治療藥市場預測 (2017∼2027年):免疫療法,化療,標靶治療,荷爾蒙療法,主力藥物

World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs

出版商 Visiongain Ltd 商品編碼 336177
出版日期 內容資訊 英文 146 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症治療藥市場預測 (2017∼2027年):免疫療法,化療,標靶治療,荷爾蒙療法,主力藥物 World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs
出版日期: 2017年09月14日 內容資訊: 英文 146 Pages
簡介

全球癌症治療藥市場2016年達到了1,020億美元。尤其免疫療法市場區隔佔市場44.1%。該市場預計至2027年以6.6%的年複合成長率擴大。

本報告提供全球癌症治療藥市場相關調查,今後的收益預測,主要各市場區隔趨勢,各地區趨勢,及加入此市場的以及主要企業的簡介等彙整。

第1章 本報告概要

第2章 癌症治療藥的簡介

  • 癌症的生理學:原因及影響
  • 非控製成長
  • 脫分化
  • 侵入性與轉移
  • 癌症的原因
  • 癌症的發病率和罹患率
  • 已開發國家
  • 腫瘤治療
  • 化療
  • 荷爾蒙療法
  • 免疫療法

第3章 市場預測

第4章 各治療法市場預測

  • 概要
  • 免疫療法
  • 化療
  • 標靶治療
  • 荷爾蒙療法

第5章 25大癌症治療藥

第6章 各地區預測

  • 各地區市場預測
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 其他

第7章 定性分析

第8章 主要企業

  • AstraZeneca Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Amgen Inc.
  • Bristol-Myers Squibb
  • GlaxoSmithKline PLC (GSK Consumer Care)
  • Johnson & Johnson
  • F. Hoffmann-la Roche AG
  • Eli Lilly and Company
  • Celgene Corporation

第9章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0236

The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 194-page report you will receive 110 tables and 101 figures - all unavailable elsewhere.

The 194-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • World cancer-treating drugs market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the world cancer-treating drugs market by its leading segments:
    • Immunotherapy
    • Chemotherapy
    • Targeted Therapy
    • Hormone Therapy

Each sector is analysed and revenue forecasts presented.

  • This report discusses and forecasts revenues of the top 25 anti-cancer drugs:
    • Avastin
    • Herceptin
    • Rituxan
    • Gleevec
    • Revlimid
    • Alimta
    • Velcade
    • Erbitux
    • Gardasil
    • Zytiga
    • Xeloda
    • Tarceva
    • Afinitor
    • Sprycel
    • Tasigna
    • Sutent
    • Nexavar
    • Xgeva
    • Zoladex
    • Yervoy
    • Vidaza
    • Treanda
    • Temodar
    • Faslodex
    • Abraxane
    • Others
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • North America: US, Canada, Mexico
    • South America: Brazil, Argentina, Paraguay, Brazil, Rest of South America
    • Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
    • Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
    • Rest of World: Middle East, Africa, Other Countries
  • This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT) . It also analyses social, technological, economic and political factors (STEP) that influence the cancer-treating drugs market

image1

  • Our study discusses the selected leading companies that are the major players in the cancer-treating drugs market:
    • AstraZeneca
    • Merck & Co., Inc. (Merck)
    • Novartis
    • Amgen
    • Bristol-Myers Squibb (BMS)
    • GlaxoSmithKline (GSK)
    • Johnson & Johnson (J&J)
    • Roche
    • Eli Lilly
    • Celgene

The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.

Visiongain's study is intended for anyone requiring commercial analyses for the world cancer-treating drugs market. You find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Global Cancer-Treating Drugs Overview
  • 1.2 Research Methodology
    • 1.2.1 Primary Research
    • 1.2.2 Secondary Research
  • 1.3 Market Evaluation & Forecasting Methodology
  • 1.4 Global Cancer-Treating Drugs Market Segmentation
    • 1.4.1 Global Top 25 Cancer Treating Drug Market
  • 1.5 Overview of Findings
  • 1.6 Why You Should Read This Report
  • 1.7 How this report delivers?
  • 1.8 Key Questions Answered by This Analytical Report
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Who is This Report For?
  • 1.11 Associated Visiongain Reports
  • 1.12 About Visiongain

2 Introduction to Cancer-Treating Drugs

  • 2.1 The Physiology of Cancer - Causes and Effects
  • 2.2 Uncontrolled Growth
  • 2.3 Dedifferentiation
  • 2.4 Invasiveness and Metastasis
  • 2.5 Causes of Cancer
  • 2.6 The Incidence and Prevalence of Cancer - Trends in the World
    • 2.6.1 Incidence
    • 2.6.2 Mortality
    • 2.6.3 Survival - Improving Odds
  • 2.7 The Developed World
    • 2.7.1 The Developing World - More Must Be Done
  • 2.8 Treating Tumours - How Can We Fight Back?
  • 2.9 Chemotherapy - The Traditional Treatment
  • 2.10 Hormone Therapies
  • 2.11 Immunotherapy - A Magic Bullet?
    • 2.11.1.1 Monoclonal Antibodies (mAbs)
    • 2.11.1.2 Cancer Vaccines
    • 2.11.1.3 Non-Specific Immunotherapies
    • 2.11.1.4 Targeted Therapies
    • 2.11.1.5 Differentiating Agents

3 Global Cancer-Treating Drug Market Forecast to 2027

4 Global Cancer Treating Drugs Market by Therapy: Market Forecast to 2027

  • 4.1 Overview
  • 4.2 Immunotherapy
  • 4.3 Chemotherapy
  • 4.4 Targeted Therapy
  • 4.5 Hormone Therapy

5 Global Top 25 Cancer Treating Drugs: Market Forecast to 2027

  • 5.1 Avastin - Roche
  • 5.2 Herceptin - Roche
  • 5.3 Rituxan - Roche
  • 5.4 Gleevec - Novartis
  • 5.5 Revlimid - Celgene
  • 5.6 Alimta - Eli Lilly and Co.
  • 5.7 Velcade - Takeda/ Janssen
  • 5.8 Erbitux - Bristol Myers Squibb/ Merck KGaA/ Eli Lilly
  • 5.9 Gardasil - Merck Sharp and Dohme Ltd
  • 5.10 Zytiga - Janssen
  • 5.11 Xeloda - Roche
  • 5.12 Tarceva - Roche
  • 5.13 Afinitor - Novartis
  • 5.14 Sprycel - Bristol Myers Squibb
  • 5.15 Tasigna - Novartis
  • 5.16 Sutent - Pfizer
  • 5.17 Nexavar - Bayer
  • 5.18 Xgeva - Amgen
  • 5.19 Zoladex - AstraZeneca
  • 5.20 Yervoy - Bristol Myers Squibb
  • 5.21 Vidaza - Celgene
  • 5.22 Treanda Cephalon/ Teva
  • 5.23 Temodar - Merck Sharp and Dohme Ltd
  • 5.24 Faslodex - AstraZeneca
  • 5.25 Abraxane - Celgene
  • 5.26 Others

6 Regional Cancer Treating Drugs Market Forecasts to 2027

  • 6.1 Regional Cancer Treating Drugs Market Forecast 2017-2027
  • 6.2 North American Cancer Treating Drugs Market Forecast 2017-2027
    • 6.2.1 US Cancer Treating Drugs Market Forecast 2017-2027
    • 6.2.2 Canada Cancer Treating Drugs Market Forecast 2017-2027
    • 6.2.3 Mexico Cancer Treating Drugs Market Forecast 2017-2027
  • 6.3 South American Cancer Treating Drugs Market Forecast 2017-2027
    • 6.3.1 Brazil Cancer Treating Drugs Market Forecast 2017-2027
    • 6.3.2 Argentina Cancer Treating Drugs Market Forecast 2017-2027
    • 6.3.3 Paraguay Cancer Treating Drugs Market Forecast 2017-2027
    • 6.3.4 Bolivia Cancer Treating Drugs Market Forecast 2017-2027
    • 6.3.5 Rest of South America Cancer Treating Drugs Market Forecast 2017-2027
  • 6.4 European Cancer Treating Drugs Market Forecast 2017-2027
    • 6.4.1 France Cancer Treating Drugs Market Forecast 2017-2027
    • 6.4.2 Germany Cancer Treating Drugs Market Forecast 2017-2027
    • 6.4.3 UK Cancer Treating Drugs Market Forecast 2017-2027
    • 6.4.4 Spain Cancer Treating Drugs Market Forecast 2017-2027
    • 6.4.5 Italy Cancer Treating Drugs Market Forecast 2017-2027
    • 6.4.6 Rest of Europe Cancer Treating Drugs Market Forecast 2017-2027
  • 6.5 Asia-Pacific Cancer Treating Drugs Market Forecast 2017-2027
    • 6.5.1 China Cancer Treating Drugs Market Forecast 2017-2027
    • 6.5.2 Japan Cancer Treating Drugs Market Forecast 2017-2027
    • 6.5.3 India Cancer Treating Drugs Market Forecast 2017-2027
    • 6.5.4 Australia Cancer Treating Drugs Market Forecast 2017-2027
    • 6.5.5 Thailand Cancer Treating Drugs Market Forecast 2017-2027
    • 6.5.6 Rest of Asia-Pacific Cancer Treating Drugs Market Forecast 2017-2027
  • 6.6 Rest of World Cancer Treating Drugs Market Forecast 2017-2027
    • 6.6.1 Middle East Cancer Treating Drugs Market Forecast 2017-2027
    • 6.6.2 Africa Cancer Treating Drugs Market Forecast 2017-2027
      • 6.6.2.1 Other Countries Cancer Treating Drugs Market Forecast 2017-2027

7 Cancer Treating Drugs Market, Qualitative Analysis, 2017-2027

  • 7.1 SWOT Analysis of the Anti-Cancer Drugs Market
    • 7.1.1 Strengths of the Market
      • 7.1.1.1 The Rising Incidence of Cancer
      • 7.1.1.2 Ample Treatment Options Available
    • 7.1.2 Weaknesses
      • 7.1.2.1 The Challenges of Drug Development
      • 7.1.2.2 The Complex Nature of Cancer
      • 7.1.2.3 Opportunities in the Anti-Cancer Drugs Market
        • 7.1.2.3.1 The Advancement of Research
        • 7.1.2.3.2 A Shift Towards Personalisation
      • 7.1.2.4 Threats Facing the Anti-Cancer Drugs Market
        • 7.1.2.4.1 The Threat of Regulation
  • 7.2 STEP Analysis of the Anti-Cancer Drugs Market
    • 7.2.1 Social Factors: The Cost of Living Longer
    • 7.2.2 Technological Developments: Making the Market Move Forward
    • 7.2.3 Economic Pressure: Treatment's Hefty Price Tag
    • 7.2.4 Political Issues: Governmental Involvement in Treatment

8 Leading Companies in Cancer Treating Drugs Market

  • 8.1 AstraZeneca Plc
    • 8.1.1 AstraZeneca Plc: Company Overview
    • 8.1.2 AstraZeneca Plc: Product Portfolio
    • 8.1.3 AstraZeneca Plc: Recent Developments
  • 8.2 Merck & Co. Inc.
    • 8.2.1 Merck & Co. Inc.: Company Overview
    • 8.2.2 Merck & Co. Inc.: Product Portfolio
    • 8.2.3 Merck & Co. Inc.: Recent Developments
  • 8.3 Novartis AG
    • 8.3.1 Novartis AG: Company Overview
    • 8.3.2 Novartis AG: Product Portfolio
    • 8.3.3 Novartis AG: Recent Developments
  • 8.4 Amgen Inc.
    • 8.4.1 Amgen Inc.: Company Overview
    • 8.4.2 Amgen Inc.: Product Portfolio
    • 8.4.3 Amgen Inc.: Recent Developments
  • 8.5 Bristol-Myers Squibb
    • 8.5.1 Bristol-Myers Squibb: Company Overview
    • 8.5.2 Bristol-Myers Squibb: Product Portfolio
    • 8.5.3 Bristol-Myers Squibb: Recent Developments
  • 8.6 GlaxoSmithKline PLC (GSK Consumer Care)
    • 8.6.1 GlaxoSmithKline PLC: Company Overview
    • 8.6.2 GlaxoSmithKline PLC: Product Portfolio
    • 8.6.3 GlaxoSmithKline PLC: Recent Developments
  • 8.7 Johnson & Johnson
    • 8.7.1 Johnson & Johnson: Company Overview
    • 8.7.2 Johnson & Johnson: Product Portfolio
    • 8.7.3 Johnson & Johnson: Recent Developments
  • 8.8 F. Hoffmann-la Roche AG
    • 8.8.1 F. Hoffmann-La Roche: Company Overview
    • 8.8.2 F. Hoffmann-La Roche: Product Portfolio
    • 8.8.3 F. Hoffmann-La Roche: Recent Developments
  • 8.9 Eli Lilly and Company
    • 8.9.1 Eli Lilly and Company: Company Overview
    • 8.9.2 Eli Lilly and Company: Product Portfolio
    • 8.9.3 Eli Lilly and Company: Recent Developments
  • 8.10 Celgene Corporation
    • 8.10.1 Celgene Corporation: Company Overview
    • 8.10.2 Celgene Corporation: Product Portfolio
    • 8.10.3 Celgene Corporation: Recent Developments

9 Conclusions

  • 9.1 The Top 25 Drugs in the Cancer Treatment Market
  • 9.2 Immunotherapies - The Future of the Market
  • 9.3 Patent Expiries and the Impact of Biosimilars
  • 9.4 The US - Still the Largest National Market
  • 9.5 China and Brazil Will Lead the Emerging Markets
  • 9.6 Treatment - It's Personal
  • 9.7 The Anti-Cancer Drug Pipeline Remains Strong
  • 9.8 Concluding Remarks

Appendices

  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2017
  • Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2017
  • Table 3.1. Global Cancer-Treating Drugs Forecast ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.1. Global Cancer Treating Drugs Market Forecast, by Therapy ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.2. Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.3. Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, by Geography, ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.4. Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.5. Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.6. Global Targeted Therapy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.7. Global Targeted Therapy Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.8. Global Hormone Therapy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 4.9. Global Hormone Therapy Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027
  • Table 5.1 Global Top 25 Cancer Treating Drugs Market, ($bn, AGR%, CAGR%) 2017-2027
  • Table 5.2. Global Avastin Revenue Forecast ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.3. Global Herceptin Revenue Forecast ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.4. Global Rituxan Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.5 Global Gleevec Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.6 Global Revlimid Revenue ($bn, AGR%, CAGR%),2017-2027
  • Table 5.7 Global Alimta Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.8 Global Velcade Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.9 Global Erbitux Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.10 Global Gardasil Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.11 Global Zytiga Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.12 Global Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%),2017-2027
  • Table 5.13 Global Tarceva Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.14 Global Afinitor Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.15 Global Sprycel Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.16 Global Tasigna Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.17 Global Sutent Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.18 Global Nexavar Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.19 Global Xgeva Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.20 Global Zoladex Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.21 Global Yervoy Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.22 Global Vidaza Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.23 Global Treanda Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.24 Global Temodar Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.25 Global Faslodex Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.26 Global Abraxane Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 5.27 Global Others Revenue ($bn, AGR%, CAGR%), 2017-2027
  • Table 6.1. Global Cancer Treating Drugs Market, by Geography ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.2. North America Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.3. US Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.4. Canada Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.5. Mexico Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.6. South America Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.7. Brazil Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.8. Argentina Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2016-2027
  • Table 6.9. Paraguay Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.10. Bolivia Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.11. Rest of South America Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.12. European Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.13. France Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.14 Germany Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.15 UK Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.16. Spain Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.17. Italy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.18. Rest of European Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.19. Asia-Pacific Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.20. China Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.21. Japan Cancer Treating Drugs Market Forecast ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.22. India Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.23. Australia Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.24. Thailand Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.25. Rest of Asia-Pacific Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.26. Rest of World Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.27. Middle East Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.28. Africa Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 6.29. Other Countries Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027
  • Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2017
  • Table 7.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2017
  • Table 8.1 AstraZeneca Plc: Company Overview
  • Table 8.2 AstraZeneca Plc: Pipeline Products
  • Table 8.3 AstraZeneca Plc: Product Portfolio
  • Table 8.4 AstraZeneca Plc: Recent Developments
  • Table 8.5 Merck & Co. Inc.: Company Overview
  • Table 8.6 Merck & Co. Ltd.: Pipeline Products
  • Table 8.7 Merck & Co. Inc.: Product Portfolio
  • Table 8.8 Merck & Co. Inc.: Recent Developments
  • Table 8.9 Novartis AG: Company Overview
  • Table 8.10 Novartis AG: Pipeline Products
  • Table 8.11 Novartis AG: Product Portfolio
  • Table 8.12 Novartis AG: Recent Developments
  • Table 8.13 Amgen Inc.: Company Overview
  • Table 8.14 Amgen Inc.: Pipeline Products
  • Table 8.15 Amgen Inc.: Product Portfolio
  • Table 8.16 Amgen Inc.: Recent Developments
  • Table 8.17 Bristol-Myers Squibb: Company Overview
  • Table 8.18 Bristol-Myers Squibb: Pipeline Products
  • Table 8.19 Bristol-Myers Squibb : Product Portfolio
  • Table 8.20 Bristol-Myers Squibb: Recent Developments
  • Table 8.21 GlaxoSmithKline PLC: Company Overview
  • Table 8.22 GlaxoSmithKline: Pipeline Products
  • Table 8.23 GlaxoSmithKline PLC: Product Portfolio
  • Table 8.24 GlaxoSmithKline PLC: Recent Developments
  • Table 8.25 Johnson & Johnson: Company Overview
  • Table 8.26 Johnson & Johnson: Pipeline Products
  • Table 8.27 Johnson & Johnson: Product Portfolio
  • Table 8.28 Johnson & Johnson: Recent Developments
  • Table 8.29 F. Hoffmann-La Roche : Company Overview
  • Table 8.30 F. Hoffmann-La Roche: Pipeline Products
  • Table 8.31 F. Hoffmann-La Roche : Product Portfolio
  • Table 8.32 F. Hoffmann-La Roche : Recent Developments
  • Table 8.33 Eli Lilly and Company: Company Overview
  • Table 8.34 F. Eli Lilly Company: Pipeline Products
  • Table 8.35 Eli Lilly and Company : Product Portfolio
  • Table 8.36 Eli Lilly and Company : Recent Developments
  • Table 8.37 Celgene Corporation: Company Overview
  • Table 8.38 Celgene Corporation: Pipeline Products
  • Table 8.39 Celgene Corporation: Product Portfolio
  • Table 8.40 Celgene Corporation : Recent Developments

List of Figures

  • Figure 1.1 Anti-Cancer Market Segmentation, 2017
  • Figure 3.1 Cancer Treating Drugs Market, by Therapy, ($bn), 2017-2027
  • Figure 4.1 Cancer Treating Drugs Market, by Therapy, Market Share (%), 2016
  • Figure 4.2 Cancer Treating Drugs Market, by Therapy, Forecast ($bn) 2017-2027
  • Figure 4.3 Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027
  • Figure 4.4 Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027
  • Figure 4.5 Global Targeted Therapy Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027
  • Figure 4.6 Global Hormone Therapy Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027
  • Figure 5.1 Global Top 25 Cancer Treating Drugs, Market Share (%), 2016
  • Figure 5.2. Global Avastin Revenue Forecast, ($bn) 2017-2027
  • Figure 5.3. Global Herceptin Revenue Forecast, ($bn) 2017-2027
  • Figure 5.4. Global Rituxan Revenue Forecast, ($bn) 2017-2027
  • Figure 5.5. Global Gleevec Revenue Forecast, ($bn, AGR%, CAGR%), 2017-2027
  • Figure 5.6. Global Revlimid Revenue Forecast, ($bn) 2017-2027
  • Figure 5.7. Global Alimta Revenue Forecast, ($bn) 2017-2027
  • Figure 5.8. Global Velcade Revenue Forecast, ($bn) 2017-2027
  • Figure 5.9. Global Erbitux Revenue Forecast, ($bn) 2017-2027
  • Figure 5.10. Global Gardasil Revenue Forecast, ($bn) 2017-2027
  • Figure 5.11. Global Zytiga Revenue Forecast, ($bn) 2017-2027
  • Figure 5.12 Global Xeloda Revenue Forecast, ($bn, AGR%, CAGR%), 2017-2027
  • Figure 5.13. Global Tarceva Revenue Forecast, ($bn) 2017-2027
  • Figure 5.14. Global Afinitor Revenue Forecast, ($bn) 2017-2027
  • Figure 5.15. Global Sprycel Revenue Forecast, ($bn) 2017-2027
  • Figure 5.16. Global Tasigna Revenue Forecast, ($bn) 2017-2027
  • Figure 5.17. Global Sutent Revenue Forecast, ($bn) 2017-2027
  • Figure 5.18 Global Nexavar Revenue Forecast, ($bn) 2017-2027
  • Figure 5.19. Global Xgeva Revenue Forecast, ($bn) 2017-2027
  • Figure 5.20. Global Zoladex Revenue Forecast, ($bn) 2017-2027
  • Figure 5.21. Global Yervoy Revenue Forecast, ($bn) 2017-2027
  • Figure 5.22 Global Vidaza Revenue Forecast, ($bn) 2017-2027
  • Figure 5.23. Global Treanda Revenue Forecast, ($bn) 2017-2027
  • Figure 5.24. Global Temodar Revenue Forecast, ($bn) 2017-2027
  • Figure 5.25. Global Faslodex Revenue Forecast, ($bn) 2017-2027
  • Figure 5.26. Global Abraxane Revenue Forecast, ($bn) 2017-2027
  • Figure 5.27. Global Others Revenue Forecast, ($bn) 2017-2027
  • Figure 6.1. Global Cancer Treating Drugs Market, by Geography, ($bn) 2017-2027
  • Figure 6.2. Global Cancer Treating Drugs Market Forecast, by Geography, Market Share (%), 2016
  • Figure 6.3. North America Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027
  • Figure 6.4. North America Cancer Treating Drugs Market, by Country, Market Share (%), 2016
  • Figure 6.5. US Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.6. Estimation of Diagnosis of Canadian Cancer Immunotherapy
  • Figure 6.7. Canada Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.8 Mexico Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.9 South America Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027
  • Figure 6.10. South America Cancer Treating Drugs Market, by Country, Market Share (%), 2016
  • Figure 6.11. Brazil Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.12. Argentina Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.13. Paraguay Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.14. Bolivia Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.15. Rest of South America Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.16. Europe Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027
  • Figure 6.17. Europe Cancer Treating Drugs Market, by Country, Market Share (%), 2016
  • Figure 6.18. France Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.19 Germany Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.20. UK Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.21. Spain Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.22. Italy Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.23. Rest of Europe Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.24. Asia-Pacific Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027
  • Figure 6.25. Asia-Pacific Cancer Treating Drugs Market, Market Share (%), 2016
  • Figure 6.26. Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.27. Japan Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.28. India Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.29. Australia Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.30. Thailand Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.31. Rest of Asia-Pacific Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.32. RoW Cancer Treating Drugs Market, by Country($bn) 2017-2027
  • Figure 6.33. Rest of World Cancer Treating Drugs Market, by Country, Market Share (%), 2016
  • Figure 6.34. Middle East Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.35. Africa Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 6.36. Other Countries Cancer Treating Drugs Market Forecast ($bn) 2017-2027
  • Figure 8.1 AstraZeneca Plc, Historical Revenue, ($billion), 2012-2016
  • Figure 8.2 AstraZeneca Plc, Product Segments Share (%), 2016
  • Figure 8.3 Merck & Co. Inc., Historical Revenue, ($Billion), 2012-2016
  • Figure 8.4 Merck & Co. Inc., Product Segments Share (%), 2016
  • Figure 8.5 Merck & Co. Inc., Geographical Presence Share (%), 2016
  • Figure 8.6 Novartis AG, Historical Revenue, ($billion), 2012-2016
  • Figure 8.7 Novartis AG, Product Segments Share (%), 2016
  • Figure 8.8 Novartis AG, Geographical Presence Share (%), 2016
  • Figure 8.9 Amgen Inc., Historical Revenue, ($billion), 2012-2016
  • Figure 8.10 Amgen Inc., Product Segments Share (%), 2016
  • Figure 8.11 Amgen Inc., Geographical Presence Share (%), 2016
  • Figure 8.12 Bristol-Myers Squibb, Revenue, ($billion), 2012-2016
  • Figure 8.13 Bristol-Myers Squibb, Product Segments Share (%), 2016
  • Figure 8.14 Bristol-Myers Squibb, Geographical Presence Share (%), 2016
  • Figure 8.15 GlaxoSmithKline PLC, Historical Revenue, ($billion), 2012-2016
  • Figure 8.16 GlaxoSmithKline PLC, Product Segments Share (%), 2016
  • Figure 8.17 GlaxoSmithKline PLC, Geographical Presence Share (%), 2016
  • Figure 8.18 Johnson & Johnson, Historical Revenue, ($Billion), 2012-2016
  • Figure 8.19 Johnson & Johnson, Product Segments Share (%), 2016
  • Figure 8.20 Johnson & Johnson, Geographical Presence Share (%), 2016
  • Figure 8.21 F. Hoffmann-La Roche, Historical Revenue, ($Billion), 2012-2016
  • Figure 8.22 F. Hoffmann-La Roche, Product Segments Share (%), 2016
  • Figure 8.23 F. Hoffmann-La Roche, Geographical Presence Share (%), 2016
  • Figure 8.24 Eli Lilly and Company, Historical Revenue, ($billion), 2012-2016
  • Figure 8.25 Eli Lilly and Company, Product Segments Share (%), 2016
  • Figure 8.26 Eli Lilly and Company, Geographical Presence Share (%), 2016
  • Figure 8.27 Celgene Corporation, Historical Revenue, ($billion), 2012-2016
  • Figure 9.1 Top 25 Anti-Cancer Drugs: Revenues ($bn), 2016
  • Figure 9.2 Global Cancer Drug Market by Geography: Revenues ($bn), 2017-2027
  • Figure 9.3 Global Cancer Drug Market by Therapy Type: Revenues ($bn), 2017-2027

Companies Listed

  • AbbVie
  • Active Biotech
  • Advaxis
  • Alchemia
  • Allergan
  • Amgen
  • AmpImmune
  • Argos Therapeutics
  • ArQule
  • AstraZeneca
  • Barvarian Nordic
  • Bayer
  • Biothera
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celator Pharmaceuticals
  • Celgene
  • Cephalon
  • Clovis Oncology
  • Cyclacel
  • Daiichi Sankyo
  • Dendreon
  • Dr. Reddy's Laboratories
  • Eisai
  • Eli Lilly
  • EMA
  • Sanofi
  • EMD Serono
  • Galena Biopharma
  • Gilead
  • GSK
  • Heat Biologics
  • Immatics Biotechnologies
  • Infinity Pharmaceuticals
  • Inovio Pharmaceuticals
  • Janssen
  • Jennerex Biotherapeutics
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson
  • MedImmune
  • Merck & Co.
  • Merck KGaA
  • Merck Sharpe and Dohme
  • Merrimack
  • Newlink
  • Novartis
  • OncoGenex
  • Onyx
  • Orion
  • OSi Pharmaceuticals
  • Petrov Institute of Oncology
  • Pfizer
  • Pharmacyclics
  • Progen Pharmaceuticals
  • Puma Biotechnology
  • Roche
  • Spectrum Pharmaceuticals
  • Spirogen
  • Sun Pharma
  • Sunesis Pharmaceuticals
  • Syndax
  • Takeda
  • Telomedix
  • TESARO
  • Teva Pharmaceuticals
  • Tracon Pharma
  • Transgene
  • United Therapeutics
  • Vaccinogen
  • Viventia Biotech
  • Xbiotech

List of Organizations Mentioned in the Report

  • American Cancer Society
  • European Commission
  • Food and Drug Administration (FDA)
  • Japanese MHLW
  • Massachusetts General Hospital
  • National Cancer Institute
  • National Comprehensive Cancer Network
  • Rose Li and Associates
Back to Top